Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Mindray’s Q1 Underwhelms Investors

publication date: May 12, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Mindray Medical International Limited (迈瑞医疗国际有限公司), the Shenzhen maker of medical devices, announced its Q1 revenues jumped 54% to $134.2 million. Net income, however, failed to keep pace with revenues, rising just 10% higher to $30.5 million on a non-GAAP basis and $25.3 million following GAAP rules. The numbers were a bit of a disappointment as analysts expected the company’s revenues to be close to $145 million, though earnings came in slightly ahead of forecasts. More details..

Stock Symbol: (NYSE: MR)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...